Inovio (INO) is the loudest small-cap gapper this morning, indicated up well over 100% pre-market (prints around $1.75–2.00 seen) after the FDA granted accelerated approval to Voceryq late Friday.
The facts
- Approved to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis (RRP), a rare HPV-6/HPV-11 driven airway disease
- First plasmid DNA-based immunotherapy approved in the US, so it's a platform validation story as much as a product one
- Based on a 32-patient open-label trial: 7 of 26 patients in the efficacy group (27%) needed no surgery in the 12 months after treatment
- It's an accelerated approval, so a confirmatory study is required (draft protocol due by end of 2026)
- Inovio expects orders/shipping in ~60 days and full launch in Q1 2027. Conference call today at 8:00 ET (13:00 London)
Things to keep in mind
- Sub-$2 stock with a big float and heavy pre-market volume, so spreads and halts are part of the game
- Small biotechs that gap on approval often raise cash quickly afterwards. Watch for an offering headline
- The 8:00 ET call can swing the pre-market range before the open
I'd treat the pre-market high and VWAP as the levels and not chase the open. Let the first 5–15 minutes show whether it holds or starts to fill.
Sources: [FDA press release](https://www.fda.gov/news-events/press-a ... llomatosis) | [Inovio IR](https://ir.inovio.com/news/news-details ... fault.aspx) | [Benzinga movers](https://www.benzinga.com/trading-ideas/ ... -premarket)
Anyone trading INO today? Do you fade approval gaps like this or wait for the dip-and-rip?
INO more than doubles pre-market after FDA accelerated approval of Voceryq for RRP, first US-approved DNA medicine
-
LondonNewsTrader
- Posts: 549
- Joined: Sat Sep 05, 2026 10:13 pm